Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM
Ahmad Masri, Cardiomyopathy Section Head at Oregon Health and Science University, shared a post on LinkedIn about a recent article by Peter C. Kahr et al., published in Nature Medicine, adding:
“Longer term data from the cliramitug depleter program in ATTR-CM.
- The furthest along in development from this new class of drugs in ATTR.
- Cliramitug – phase III ongoing.
- Coramitug – enrolling now in phase III.
- AT02 – phase I-II.
2 new depleters in the preclinical settings – one from BridgeBio and one from Immutrin.”
Title: Cliramitug for depletion of cardiac amyloid transthyretin: long-term follow-up of the NI006-101 trial
Authors: Peter C. Kahr, Fabian aus dem Siepen, Olivier Lairez, Erwan Donal, Thibaud Damy, Arnt V. Kristen, Cristina C. Quarta, Michele F. Mercuri, Sarah Keppner-Witter, Eva Herrmann-Keiner, Mia Tichy, Aubin Michalon, Jan Grimm, Roger M. Nitsch, Christoph Hock, Pablo Garcia-Pavia, Peter van der Meer
Stay updated with Hemostasis Today.
-
Oct 9, 2026, 16:23David Boone: Distinguishing Stroke Prevention from Rhythm Control in Atrial Fibrillation
-
Oct 9, 2026, 15:27Mohamed Hegazi: Geostatistical Modelling Maps Global β-Thalassaemia Carrier Prevalence
-
Oct 9, 2026, 15:15Maha Othman: Uncovering the Consensus on TXA in TBI – Call for Collaboration on a Landmark Umbrella Review
-
Oct 9, 2026, 15:07Daniel D. Han: How Inhalation Product Exposure Impairs Cardiac and Platelet Recovery After MI
-
Oct 9, 2026, 14:58William Toole: How Ultrasound-Guided PRP Therapy Relieves Joint and Tendon Pain
-
Oct 9, 2026, 14:50Shayan Mohammadmoradi: In Corpus Christi for the 20th Midwest Platelet Conference
-
Oct 9, 2026, 14:37Tariq Tramboo: High Platelet Concentrate for Osteoarthritis Knee – Recent Meta-Analyses
-
Oct 9, 2026, 14:26Yousma Khan: Hematology Series – Beyond RBCs, WBCs and Platelets
-
Oct 9, 2026, 14:13Jesus Ardila Novoa: Why the WHO’s Historic Essential Medicines List Decision Is Just the Beginning